Christian Sire

1.8k total citations
21 papers, 329 citations indexed

About

Christian Sire is a scholar working on Otorhinolaryngology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Christian Sire has authored 21 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Otorhinolaryngology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Oncology. Recurrent topics in Christian Sire's work include Head and Neck Cancer Studies (20 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (6 papers). Christian Sire is often cited by papers focused on Head and Neck Cancer Studies (20 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (6 papers). Christian Sire collaborates with scholars based in France, Switzerland and Belgium. Christian Sire's co-authors include Jean Bourhis, Laurent Martin, Cédrik Lafond, Alexandre Coutté, Lionnel Geoffrois, J. Guigay, Yungan Tao, Anne Aupérin, Frédéric Rolland and M. Alfonsi and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Clinical Nutrition and The Lancet Oncology.

In The Last Decade

Christian Sire

20 papers receiving 324 citations

Peers

Countries citing papers authored by Christian Sire

Since Specialization

Citations

This map shows the geographic impact of Christian Sire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian Sire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian Sire more than expected).

Fields of papers citing papers by Christian Sire

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christian Sire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian Sire. The network helps show where Christian Sire may publish in the future.

Co-authorship network of co-authors of Christian Sire

This figure shows the co-authorship network connecting the top 25 collaborators of Christian Sire. A scholar is included among the top collaborators of Christian Sire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christian Sire. Christian Sire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial 2024 ·Radiotherapy and Oncology ·Christian Borel, Xu-Shan Sun, Alexandre Coutté, G. Béra, Christian Sire, Sylvie Zanetta, M. Alfonsi, (unknown), Thierry Chatellier, (unknown), (unknown), (unknown), (unknown), Nelly Étienne-Selloum, (unknown), (unknown), Michel Velten, Jean‐Pierre Pignon, (unknown), Jean Bourhis	2
2	Long-term Results from a Clinical Study of Xevinapant Plus Chemoradiotherapy in People With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Plain Language Summary 2023 ·Future Oncology ·Yungan Tao, Xu-Shan Sun, Y. Pointreau, Christophe Le Tourneau, Christian Sire, Kathrin Gollmer, (unknown), Jean Bourhis	3
3	Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010–02) 2022 ·European Journal of Cancer ·S. Racadot, (unknown), (unknown), Marie‐Christine Kaminsky, M. Bosset, Laurent Martin, Yungan Tao, Christian Sire, D. De Raucourt, M. Alfonsi, Emmanuelle Malaurie, Jean‐Marc Tourani, P. Fournel, Élodie Vauléon, A. Modesto, Frédéric Rolland, (unknown), P. Pommier, Sylvie Chabaud, Sophie Dussart	2
4	Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH) 2020 ·European Journal of Cancer ·Yungan Tao, Anne Aupérin, Xu-Shan Sun, Christian Sire, Laurent Martin, Alexandre Coutté, Cédrik Lafond, J. Miroir, X. Liem, Frédéric Rolland, Caroline Even, (unknown), Esma Saâda, Aline Maillard, (unknown), Juliette Thariat, J. Guigay, Jean Bourhis	58
5	A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX 2020 ·American Journal of Clinical Nutrition ·Pierre Boisselier, Marie‐Christine Kaminsky, Simon Thézenas, (unknown), Sandrine Lavau‐Denès, (unknown), M. Alfonsi, Didier Cupissol, Hélène de Forges, (unknown), Lionnel Geoffrois, Christian Sire, Pierre Sénesse	27
6	<p>Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer</p> 2020 ·Patient Preference and Adherence ·Y. Pointreau, René‐Jean Bensadoun, G. Béra, Christian Sire, (unknown), (unknown), G. Calais, Marc A. Bollet, (unknown), Viorica Braniste, (unknown)	8
7	TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 2020 ·Journal of Clinical Oncology ·J. Guigay, Jérôme Fayette, Ricard Mesı́a, Esma Saâda-Bouzid, Cédrik Lafond, Lionnel Geoffrois, Laurent Martin, Olivier Capitain, Didier Cupissol, H. Castanie, Alison Johnson, Damien Vansteene, Caroline Even, Christian Sire, (unknown), (unknown), (unknown), Ulrich Keilholz, Jean Bourhis, Anne Aupérin, (unknown)	14
8	TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). 2019 ·Journal of Clinical Oncology ·J. Guigay, Jérôme Fayette, Ricard Mesı́a, Cédrik Lafond, Esma Saâda-Bouzid, Lionnel Geoffrois, Laurent Martin, Didier Cupissol, Olivier Capitain, H. Castanie, Damien Vansteene, Philippe Schafhausen, Catherine Dubos Arvis, (unknown), Christian Sire, (unknown), Cécile Michel, Jean Bourhis, Ulrich Keilholz, Anne Aupérin, (unknown)	46
9	ELAN-ONCOVAL (Elderly Head and Neck Cancer-Oncology Evaluation) study: Evaluation of the G8 screening tool and the ELAN geriatric evaluation (EGE) for elderly patients (pts) with head and neck squamous cell carcinomas (HNSCC). 2019 ·Journal of Clinical Oncology ·C. Mertens, H. Le Caer, Cécile Ortholan, Emmanuel Blot, Caroline Even, Hubert Rousselot, Frédéric Peyrade, Christian Sire, Didier Cupissol, Y. Pointreau, P. Debourdeau, Frédéric Rolland, Jérôme Fayette, Olivier Capitain, Xu Sun, (unknown), Rabia Boulahssass, (unknown), Anne Aupérin, J. Guigay	7
10	Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH). 2018 ·Journal of Clinical Oncology ·Yungan Tao, Anne Aupérin, Xu Sun, Christian Sire, Laurent Martin, G. Béra, Alexandre Coutté, J. Miroir, Cédrik Lafond, (unknown), Aline Maillard, (unknown), Cécile Michel, J. Guigay, Jean Bourhis	17
11	Hyperfractionated reirradiation with cetuximab for recurrent head and neck cancer: The GORTEC 2008-01 multicentric phase II study. 2018 ·Journal of Clinical Oncology ·(unknown), Yungan Tao, M. Alfonsi, Pierre Boisselier, (unknown), C. Tuchais, P. Maingon, Christian Sire, Ali Hasbini, (unknown), Cédrik Lafond, Hao Qiu, S. Guihard, P. Garaud, (unknown), Juliette Thariat, Laurent Martin, Jean Bourhis, (unknown)	2
12	A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial. 2018 ·Journal of Clinical Oncology ·Xu Sun, Christian Sire, Yungan Tao, Laurent Martin, M. Alfonsi, (unknown), Michel Rives, Cédrik Lafond, Jean‐Marc Tourani, J. Biau, Lionnel Geoffrois, Alexandre Coutté, X. Liem, Élodie Vauléon, Franck Drouet, Jean‐François Ramée, (unknown), (unknown), Anne Aupérin, Jean Bourhis	42
13	Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials 2017 ·Oral Oncology ·Yungan Tao, Anne Aupérin, P. Gräff, M. Lapeyre, Vincent Grégoire, P. Maingon, L. Geoffrois, Pierre Verrelle, G. Calais, B. Géry, Laurent Martin, M. Alfonsi, (unknown), É. Bardet, T. Pignon, Michel Rives, Christian Sire, Jean Bourhis	10
14	Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients 2017 ·International Journal of Radiation OncologyBiologyPhysics ·Yungan Tao, Anne Aupérin, Christian Sire, Michel Martin, (unknown), É. Bardet, Xu Sun, Thierry Chatellier, Clotilde Morand, (unknown), (unknown), (unknown), (unknown), Pierre Blanchard, (unknown), Jean Bourhis	12
15	Impact of p16 expression on induction taxotere-cisplatin-5 FU (TPF) followed by cetuximab-radiotherapy in N2b-N3 head and neck squamous cell carcinoma (HNSCC): Results of GORTEC 2007-02 phase III randomized trial. 2017 ·Journal of Clinical Oncology ·Yungan Tao, Lionnel Geoffrois, Laurent Martin, D. De Raucourt, (unknown), P. Maingon, Cédrik Lafond, C. Tuchais, Christian Sire, E. Babin, Alexandre Coutté, Frédéric Rolland, (unknown), Odile Casiraghi, P. Garaud, Jean Bourhis	6
16	Cetuximab-radiotherapy versus cetuximab-radiotherapy plus concurrent chemotherapy in patients with N0-N2a squamous cell carcinoma of the head and neck (SCCHN): Results of the GORTEC 2007-01 phase III randomized trial. 2016 ·Journal of Clinical Oncology ·Jean Bourhis, Xu Sun, Christian Sire, Yungan Tao, Laurent Martin, (unknown), P. Maingon, É. Bardet, M. Lapeyre, Thierry Chatellier, (unknown), (unknown), Anne Aupérin	12
17	Induction docetaxel platinum 5-FU (TPF) followed by cetuximab-radiotherapy (cetux-RT) versus concurrent chemo-radiotherapy (CT/RT) in patients with N2b/c-N3 non operated stage III-IV squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial. 2016 ·Journal of Clinical Oncology ·Lionnel Geoffrois, Laurent Martin, P. Garaud, D. De Raucourt, (unknown), P. Maingon, Cédrik Lafond, C. Tuchais, Christian Sire, E. Babin, Alexandre Coutté, Yungan Tao, Frédéric Rolland, (unknown), Jean Bourhis	26
18	Double blind multicenter phase III GORTEC trial evaluating the efficacy of oral immune modulating formulae therapy during adjuvant radiochemotherapy in head and neck squamous cell carcinoma (HNSCC). 2015 ·Journal of Clinical Oncology ·Pierre Boisselier, P. Graff-Cailleaud, Christian Sire, (unknown), Sandrine Lavau‐Denès, (unknown), M. Alfonsi, Didier Cupissol, Marie‐Christine Kaminsky, (unknown), Nicolas Flori, Hélène de Forges, R. Garrel, (unknown), Simon Thézenas, Pierre Sénesse	0
19	Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03. 2012 ·Journal of Clinical Oncology ·J. Guigay, Jérôme Fayette, Anne-Françoise Dillies, Christian Sire, Joseph Kerger, Isabelle Tennevet, Jean‐Pascal Machiels, Sylvie Zanetta, Y. Pointreau, L. Bozec Le Moal, (unknown), (unknown), Stéphane Temam, (unknown)	25
20	Absent benefit of accelerated concomitant chemoradiotherapy – Authors' reply 2012 ·The Lancet Oncology ·Jean Bourhis, (unknown), Pierre Blanchard, Christian Sire, Anne Aupérin	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact